弥漫性中线胶质瘤病例报告（表1）
包含一例弥漫性中线胶质瘤患者的个性化治疗病例报告表格，涉及离体药物敏感性测试。
基本信息
资源简介
弥漫性中线胶质瘤病例报告（表1）
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 1 个文件、合计 17.91 KB，主题涵盖 diffuse midline glioma、functional precision medicine、drug sensitivity testing、molecular guided therapy、pediatric brain cancer，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Table 1_Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma.xlsx》。配套论文《A comprehensive multicenter analysis of clinical, molecular, and imaging characteristics and outcomes of H3 K27–altered diffuse midline glioma in adults》发表于 Journal of Neurosurgery（2025），DOI：10.3171/2024.8.JNS241180。源站首次发布：2025-08-07。
【数据内容】
源站原始描述：Diffuse midline glioma (DMG) is a pediatric brain cancer that has a dismal prognosis with limited treatment options. We present the treatment course and outcome of an adolescent male diagnosed with a thalamic DMG carrying a histone H3.3 K27M (H3K27M) alteration. Tumor biopsies were taken at diagnosis for histological analysis, molecular profiling, and ex vivo drug sensitivity testing (DST). Seven months after diagnosis, the patient had recurrent/progressive disease after radiotherapy and an inef…
【数据结构与技术规格】
文件数 1 个，合计 17.91 KB。Table 1_Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline.xlsx：application/vnd.openxmlformats-officedocument.spreadsheetml.sheet，17.91 KB。数据集 DOI：10.3389/fonc.2025.1606575.s001。
【主题与分类】
源站学科分类：Oncology and Carcinogenesis not elsewhere classified。主题标签：diffuse midline glioma、functional precision medicine、drug sensitivity testing、molecular guided therapy、pediatric brain cancer。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_Case_Report_Application_of_ex-vivo_drug_sensitivity_testing_to_identify_personalized_treatment_options_for_an_adolescent_with_diffuse_midline_glioma_xlsx/29849390
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Tan, Philip K.; Martins, Timothy J.; Becker, Pamela S.; Wechsler-Reya, Robert J.; Crawford, John Ross (2025). Table 1_Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma.xlsx. Frontiers. Dataset
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：Table 1_Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma.xlsx
- DOI：10.3389/fonc.2025.1606575.s001
- 发布日期：2025-08-07
- 文件数：1 个
- 文件总体积：17.91 KB
- 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_Case_Report_Application_of_ex-vivo_drug_sensitivity_testing_to_identify_personalized_treatment_options_for_an_adolescent_with_diffuse_midline_glioma_xlsx/29849390
命令行下载
curl -L -o "Table 1_Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline.xlsx" "https://ndownloader.figshare.com/files/56999216"
文件清单
Table 1_Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline.xlsx（17.91 KB）
文件总体积 17.91 KB（源站 API 实测）。
数据说明
Diffuse midline glioma (DMG) is a pediatric brain cancer that has a dismal prognosis with limited treatment options. We present the treatment course and outcome of an adolescent male diagnosed with a thalamic DMG carrying a histone H3.3 K27M (H3K27M) alteration. Tumor biopsies were taken at diagnosis for histological analysis, molecular profiling, and ex vivo drug sensitivity testing (DST). Seven months after diagnosis, the patient had recurrent/progressive disease after radiotherapy and an ineffective molecular-guided therapy based on tumor molecular profiling. The patient then started a novel functional precision medicine (FPM)-guided two-drug combination of disulfiram, based on the DST results of this drug on the patient’s tumor cells obtained at diagnosis, and ONC 201, the only drug that has advanced to a phase III clinical trial for H3K27M-DMG. Neuroimaging demonstrated a treatment response, and the patient lived for fifteen months after starting this personalized therapy. Disulfiram was discontinued after three months due to significant peripheral neuropathy. Our case describes the feasibility and limitations of using DST of patient-derived tumor cells to identify potentially effective personalized and novel therapies for DMG, which should be evaluated for efficacy and safety in formal N-of-1 clinical trials settings. We discuss the benefits and risks of this approach, particularly considering its use in children, adolescents, and young adults with pediatric brain cancers.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.3389/fonc.2025.1606575.s001（source: https://frontiersin.figshare.com/articles/dataset/Table_1_Case_Report_Application_of_ex-vivo_drug_sensitivity_testing_to_identify_personalized_treatment_options_for_an_adolescent_with_diffuse_midline_glioma_xlsx/29849390）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
